Abstract library

38 results for "srs".
#2282 Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest
Introduction: Neuroendocrine neoplasms of the appendix (ANEN) are one of the most commonly identified gastroentropancreatic tumours (GEP). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy (SRS) in staging and imaging follow-up of patients with confirmed ANEN, NENG1 and NENG2 in single institution.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Sonia Konsek
#1565 Molecular Imaging of Late Somatostatin Receptor–Positive Metastases of Renal Cell Carcinoma in the Pancreas by Radiolabeled 111In SRS Octreotide Scan : A Rare Differential Diagnosis to Multiple Primary Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin-Receptor Scintigraphy (SRS) has a sensitivity and specificity for pancreatic NETs (pNETs) of 90 and 80% respectively. SRS is indicated as first staging procedure and one of the most sensitive imaging modalities for well-differentiated neuroendocrine tumors, based on imaging of somatostatin receptors (SSRTs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Georgios Dimitriadis
Keywords: SRS, pNET, SSRTs, RCC
#978 Prognostic Value of Somatostatin Receptor Scintigraphy on High-Grade Neuroendocrine Neoplasms and Impact on the Treatment Decision of Intermediate-Grade Neuroendocrine Neoplasms
Introduction: Somatostatin receptor scintigraphy (SRS) could detect not only somatostatin receptors but also tumor images in patients with neuroendocrine neoplasms (NENs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Jian Ming Xu
Authors: Jia R, Fu Y L, Lin L, Wang Y, ...
#2242 Diagnostic Utility of Ki-67 as a Mean to Predict the Uptake of Functional Imaging Modalities in Patients with Neuroendocrine Neoplasms
Introduction: Functional imaging with FDG-PET and somatostatin receptors scintigraphy (SRS), play a key role in the diagnosis, treatment and follow-up of patients with neuroendocrine neoplasms (NENs). The proliferative index, ki67, is a reliable pathological marker for grading.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Krystallenia Alexandraki
Keywords: SRS, PET-FDG, ki-67, NENs
#760 Intraoperative Gamma Probe Detection of Metastatic Medullary Thyroid Carcinoma (MTC) with 111In-Pentetreotide
Introduction: MTC is a rare thyroid malignancy representing approximately 5-10% of all thyroid tumors. Early diagnosis and radical surgery are essential to reduce the morbidity and mortality associated with MTC. Somatostatin receptors (SSTRs) expression has been described in MTC with a variable pattern, SSTR2 being prevalent. Although somatostatin analogues demonstrated poor efficacy in the control of MTC growth, SSTR expression can be useful in Nuclear Medicine diagnostic procedures. 111In-pentetreotide scintigraphy and 68Ga-somatostatin analogues PET-CT represent valuable techniques in the detection of MTC, although with a lower sensitivity compared to 18F-DOPA PET-CT.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Laura De Marinis
Keywords: mtc, srs
#1048 The Additional Value of Somatostatin Receptor Scintigraphy During Preoperative Staging in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors.
Introduction: During diagnostic workup for non-functioning pancreatic neuroendocrine tumors (NF-pNET) both computed tomography scan (CT-scan) and somatostatin receptor scintigraphy (SRS) are made.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Anneke Jilesen
#1299 Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
#1300 Staging of Neuroendocrine Tumors: Value of Hybrid Imaging With 111In- Pentetreotide
Introduction: Neuroendocrine tumors (NET) are rare and can occur anywhere in the body. Ninety-eight percent of these tumors express the type 2 of somatostatin receptors, making possible the functional imaging of NET. 111In-labelled pentetreotide specifically binds to somatostatin receptors, with particular affinity to subtypes 2 and 5.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
#1874 Value of Somatostatin Receptor Imaging (SRI) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Base on Clinical Follow-Up
Introduction: Neuroendocrine neoplasms of the appendix are common GEP-NEN tumors.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sonia Konsek
#135 The importance of endoscopic ultrasound in detecting recurrent gastrinoma in a case of MEN 1
Introduction: Approximately 25-30% of patients have gastrinomas as part of the inherited syndrome Multiple Endocrine Neoplasia 1 (MEN 1). Gastrinomas occur in the pancreas, duodenum or peripancreatic lymph nodes. Diagnosis is made by clinical history, gastroscopy, and measurement of serum gastrin, gastric juice pH, CT scan, endoscopic ultrasound (EUS) and somatostatin receptor scintigraphy (SRS). Localization of gastrinomas in patients with MEN 1 is challenging due to their small size, frequent duodenal location, and multiplicity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis